Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON‐HF trial

AIMS: In the heart failure (HF) with preserved ejection fraction (HFpEF) PARAGON‐HF trial, sacubitril/valsartan vs. valsartan improved mortality/morbidity in patients with left ventricular ejection fraction (LVEF) below median (57%). We assessed eligibility for sacubitril/valsartan based on four sce...

Descripción completa

Detalles Bibliográficos
Autores principales: Lund, Lars H., Savarese, Gianluigi, Venkateshvaran, Ashwin, Benson, Lina, Lundberg, Anna, Donal, Erwan, Daubert, Jean‐Claude, Oger, Emmanuel, Linde, Cecilia, Hage, Camilla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788030/
https://www.ncbi.nlm.nih.gov/pubmed/34811954
http://dx.doi.org/10.1002/ehf2.13705

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788030/
https://www.ncbi.nlm.nih.gov/pubmed/34811954
http://dx.doi.org/10.1002/ehf2.13705

Ejemplares similares